Akeso Biopharma, Inc.
Akeso Biopharma, Inc., a leading biopharmaceutical company headquartered in China, is at the forefront of innovative drug development. Founded in 2012, Akeso has rapidly established itself within the biotechnology industry, focusing on the research, development, and commercialisation of monoclonal antibodies and other biologics. With a strong presence in major operational regions across Asia and beyond, Akeso is renowned for its unique portfolio of core products, including innovative therapies for oncology and autoimmune diseases. The company has achieved significant milestones, including successful clinical trials and partnerships that enhance its market position. Akeso's commitment to advancing healthcare through cutting-edge biopharmaceutical solutions underscores its reputation as a key player in the global biopharma landscape.
DitchCarbon Score
How does Akeso Biopharma, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Akeso Biopharma, Inc.'s score of 20 is lower than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Akeso Biopharma, Inc.'s reported carbon emissions
Akeso Biopharma, Inc., headquartered in China (CN), currently does not report any carbon emissions data, as indicated by the absence of specific figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. This lack of emissions data and climate commitments suggests that Akeso Biopharma may not yet have established a formal framework for addressing its carbon footprint or engaging in sustainability initiatives. In the broader context of the biopharmaceutical industry, many companies are increasingly adopting science-based targets and committing to significant reductions in greenhouse gas emissions. However, without specific data or commitments from Akeso Biopharma, it remains unclear how the company aligns with these industry trends. As the focus on climate action intensifies, it will be essential for Akeso Biopharma to consider developing and communicating its climate strategy to meet stakeholder expectations and contribute to global sustainability efforts.
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Akeso Biopharma, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
